UCon 贴片电极的安全性和性能
UCon 贴片电极治疗膀胱过度活动症 (OAB) 和肠功能障碍 (BD) 的安全性和性能 - 一项关键的临床研究
UCon is a medical device for treating the symptoms of overactive bladder (OAB) and bowel dysfunction (BD). It electrically stimulates the DGN through the skin to obtain modulated behavior of the bladder/bowel musculature e.g., suppressing undesired bladder/bowel activity to relieve the symptoms of the patient.
This pivotal clinical investigation is designed as a stratified-randomized, single-blinded, controlled, confirmatory, prospective, multicenter clinical investigation.
研究概览
地位
详细说明
The overall purpose of this pivotal clinical investigation is to evaluate the UCon device with a Patch Electrode with respect to clinical safety and device performance in a cohort of 180 patients with OAB/BD over a period of 12 weeks.
The participants participate in a 12-week intervention period. For weeks 1-6, participants will be randomized (2:1 randomization) to either a treatment group using UCon-Patch with Time Limited stimulation or a sham group using UCon-Sham with sham stimulation. Participants in the treatment group will receive the actual stimulation with the intent of improving their symptoms, whereas those in the sham group will receive sham stimulation for short periods of time believed not to be capable of improving their symptoms.
For weeks 7-12 of the intervention periods, the treatment group has the opportunity to add Urge stimulation to the Time Limited stimulation, while the sham group shifts to using UCon-Patch Time Limited stimulation.
To assess the safety and performance of the UCon device on equal terms with similar devices in the market, the full intervention period with UCon will be conducted over 12 weeks, evaluating safety aspects of UCon on longer terms and confirming continued effects after 6 weeks in the treatment group. Additional analyses on data related to primary and secondary endpoints with safety and performance data from the 12-week follow-up will also be performed, but the primary analysis will focus on baseline and 6-week follow-up data.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Dianna Mærsk Knudsen
- 电话号码:+45 40517712
- 邮箱:dmk@innoconmedical.dk
学习地点
-
-
-
Aarhus、丹麦、8200
- 招聘中
- Aarhus University Hospital
-
接触:
- Peter Christensen, MD
- 电话号码:+45 20375471
- 邮箱:petchris@rm.dk
-
首席研究员:
- Jakob Jakobsen, MD
-
Herlev、丹麦、2730
- 招聘中
- Herlev Hospital
-
接触:
- Niels Klarskov, MD
- 电话号码:+45 38681406
- 邮箱:Niels.Klarskov@regionh.dk
-
Odense、丹麦、5000
- 招聘中
- Odense University Hospital
-
接触:
- Mark Bremholm Ellebæk, MD
- 电话号码:+45 40880511
- 邮箱:Mark.Ellebaek1@rsyd.dk
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participant is ≥ 18 years of age.
- Participant is diagnosed with OAB or BD.
- Participant is able to consent, communicate, provide feedback, and understand and follow instructions in Danish during the course of the investigation, including operation of the device at home.
Exclusion Criteria:
-
Participant has genital anatomy that does not allow for proper electrode placement or stimulation of the DGN.
-
Participant has an active infection in the genital area, including skin infections.
-
Participant has injured or irritated skin in the genital area, where the electrode is placed.
-
Participant is medically unstable (acute illness or complication of a chronic condition, apart from the OAB or BD, that might affect the participant's participation in the investigation).
-
Participant has an implanted pacemaker, implantable drug pump or other active medical devices (any medical device that uses electrical energy or other sources of power to make it function).
-
Participant is pregnant, nursing, planning a pregnancy (to be confirmed with a negative pregnancy test) or has given birth within the previous 12 months. Women of childbearing potential must maintain effective contraception* during the clinical investigation.
-
Participant is enrolled or planning to enroll in another conflicting clinical investigation or was enrolled in an investigational drug trial within the previous 12 weeks or medical device investigation within 12 weeks of enrolment.
-
Participant has previously participated in a clinical investigation with UCon.
-
Participant has failed (lack of effectiveness) other neuromodulation treatments, e.g. sacral neuromodulation (SNM) within the previous 2 years.
-
Participant has a neurological disease, e.g., chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, stroke, central nervous system (CNS) tumors, Parkinson´s, spinal cord injury, diabetic neuropathy, Guillain-Barré syndrome.
-
Participant has a history of cancer in the pelvic region, is currently receiving cancer treatment, or has received radiation therapy in the pelvic region.
-
Participant had surgery in the pelvic region within the previous 6 months. If it can be excluded that the participant's symptoms are related to the surgery, they can be included in the clinical investigation.
-
Participant has addictive behavior defined as the abuse of alcohol, cannabis, opioids, or other intoxicating drugs.
- The following contraception is considered effective: Intrauterine device, hormonal contraceptives such as birth control pills, implants, contraceptive patch, vaginal ring, and contraceptive injection.
Exclusion Criteria specific for OAB:
- Participant is planning or has a scheduled surgery/diagnostic procedure (within the duration of their participation) for any condition, that would require catheterization. Or have a prolonged hospitalization that would affect the ability to complete the stimulation.
- Participant (male) has symptoms of bladder outlet obstruction, e.g., caused by benign prostatic hyperplasia or prostate cancer.
- Participant has polyuria or symptoms of polyuria.
- Participant has a current or reoccurring urinary tract infection (≥3 or more within the previous 12 months or ≥2 within the previous 6 months).
- Participant has a primary diagnosis of stress urinary incontinence (SUI) or mixed incontinence with SUI likely to confound outcome measures.
- Participant has Bladder Pain Syndrome or interstitial cystitis.
- Participant has had botulinum toxin (BOTOX) treatment in the pelvic region within 9 months or has lasting benefit from BOTOX.
- Participant has failed (lack of effectiveness) BOTOX treatment within the previous 2 years.
- Participants who demonstrate detrusor overactivity on a urodynamic test can be included.
- Participant has used antimuscarinics or β3 agonists within 2 weeks.
- Participant has started oestrogen therapy within 3 months or are planning to stop therapy when enrolled in the clinical investigation.
Exclusion Criteria specific for BD:
- Participant is planning or has a scheduled surgery/diagnostic procedure (within the duration of their participation), for any condition, that would influence their bowel movements (e.g., injection of bulking agents, radiofrequency energy, or ligation of haemorrhoids). Or have a prolonged hospitalization that would affect the ability to complete the stimulation.
- Participant is currently being treated with antibiotics.
- Participant has a history of uncontrolled diarrhoea in the past 3 months (usual or most common stool type over the preceding 3 months of 7 on the Bristol Stool Form Scale).
- Participant has a history of severe constipation in the past 3 months (usual or most common stool type over the preceding 3 months of 1 on the Bristol Stool Form Scale).
- Participant has a history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis). Participants with irritable bowel syndrome can be included in the clinical investigation.
- Participant has undergone major anorectal or bowel surgery or has ongoing anorectal or bowel conditions where primary surgery is considered the best, e.g., congenital anorectal malformation, bowel resection surgery, unrepaired rectovaginal fistula, chronic 4th degree anal sphincter laceration, full thickness rectal/anal prolapse. If it can be excluded that the participant's symptoms are related to any of the above surgeries/conditions, they can be included in the clinical investigation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment group
Electrical stimulation (Time Limited stimulation) to the dorsal genital nerve. |
The participant self-administer 30 min. of electrical stimulation using Time Limited stimulation to the dorsal genital nerve (DGN) for 6 weeks using UCon with the UCon-Patch electrode.
其他名称:
|
|
假比较器:Sham group
Sham stimulation to the dorsal genital nerve. |
The participant self-administer 30 min. of sham stimulation to the dorsal genital nerve (DGN) for 6 weeks using a sham device with the UCon-Patch electrode.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of serious adverse device effects (SADEs).
大体时间:At 12 weeks.
|
Number of SADEs. |
At 12 weeks.
|
|
Ratio of treatment change [performance] of OAB symptoms.
大体时间:Change from baseline at 6 weeks.
|
Percentage of participants using UCon-Patch, compared to participants using UCon-Sham, demonstrating at least a 50% reduction in Urinary Urgency (UU) voids (with or without Urgency Urinary Incontinence, UUI). |
Change from baseline at 6 weeks.
|
|
Ratio of treatment change [performance] of BD symptoms.
大体时间:Change from baseline at 6 weeks.
|
Percentage of participants using UCon-Patch, compared to participants using UCon-Sham, demonstrating at least a 50% reduction in Faecal Urgency (FU) episodes OR at least a 50% reduction in Faecal Incontinence (FI) episodes. |
Change from baseline at 6 weeks.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of adverse events (AEs).
大体时间:At 12 weeks.
|
Number of AEs. |
At 12 weeks.
|
|
Ratio of treatment change [performance] of Urgency Urinary Incontinence.
大体时间:Change from baseline at 6 weeks.
|
Percentage of participants using UCon-Patch, compared to participants using UCon-Sham, demonstrating at least a 50% reduction in Urgency Urinary Incontinence (UUI). |
Change from baseline at 6 weeks.
|
|
Self-reported quality of life measures as assessed by the International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Module (ICIQ-OABqol) questionnaire.
大体时间:Change from baseline at 6 weeks.
|
The ICIQ-OABqol score of participants using UCon-Patch, compared to participants using UCon-Sham (scores can range from 0 to 100, with lower values indicating higher QoL). |
Change from baseline at 6 weeks.
|
|
Faecal Urgency (FU) episodes.
大体时间:Change from baseline at 6 weeks.
|
Mean reduction in number of Faecal Urgency (FU) episodes of participants using UCon-Patch, compared to participants using UCon-Sham. |
Change from baseline at 6 weeks.
|
|
Faecal Incontinence (FI) episodes.
大体时间:Change from baseline at 6 weeks.
|
Mean reduction in number of Faecal Incontinence (FI) episodes of participants using UCon-Patch, compared to participants using UCon-Sham. |
Change from baseline at 6 weeks.
|
|
Self-reported quality of life measures as assessed by the Rockwood Fecal Incontinence Quality of Life Scale (FIQL) questionnaire.
大体时间:Change from baseline at 6 weeks.
|
The FIQL score of participants using UCon-Patch, compared to participants using UCon-Sham (the scale consists of 4 scales, with each scale ranging from 1-5, with 1 indicating a lower functional QoL). |
Change from baseline at 6 weeks.
|
合作者和调查者
调查人员
- 首席研究员:Peter Christensen, MD、Palle Juul Jensens Boulevard 99 DK-8200 Aarhus N
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.